Capital Access Group Flash Notes | TheraCryf: FY26 results – Ox-1 programme on track
TheraCryf has announced results for the year to March 2026 in line with management’s expectations. Closing net cash was £1.5m, ahead of the post-period-end equity raise of £1.05m, leaving the company funded through FY27. More importantly, TheraCryf advanced the programme for its Ox-1 lead clinical asset flawlessly and is approaching more value inflection points ahead of first in-human trials. The target market for Ox-1 is currently worth US$42bn and growing rapidly. The company is completing the remaining clinic-enabling activities and continues to engage with potential commercial partners to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.